Homologous tumor cell exosome-based drug delivery system co-delivering temozolomide and resveratrol for orthotopic glioblastoma therapy
Pharmaceutical Science Advances · 2025-12 · 3 · 100075
DOI: 10.1016/j.pscia.2025.100075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Science Advances, 2025-12. Verfasst von Xuemei Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Yantai University, 30# Qingquan Road, Yantai, 264005, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Yantai University, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Temozolomide (TMZ) is the first-line chemotherapeutic agent for treating glioblastoma multiforme (GBM), but its potency is hampered by inevitable drug resistance and systematic toxicity. Novel strategies that can decrease drug-associated adverse events are urgently needed. Encouraged by the significant pro-apoptotic, anti-inflammatory, and anti-proliferative properties of resveratrol (RES), one of the most widely studied polyphenolic compounds in cancer therapy, we propose a synergistic therapeutic strategy by using the combination of TMZ and RES to inhibit GBM progression. Recently, exosomes (Exos) have received increasing attention as promising drug delivery alternatives with favorable intrinsic features. In this work, Exos derived from homologous U87 cells are developed to co-deliver TMZ/RES for GBM therapy, defined as U87-Exos@TMZ/RES. It is found that U87-Exos@TMZ/RES share various advantages, including intrinsic tumor-targeting accumulation with homologous effects, as well as enhanced antitumor activity with synergistic effects of TMZ and RES. Furthermore, the excellent therapeutic effect of U87-Exos@TMZ/RES is also achieved in orthotopic GBM models. Based on these results, this novel U87-Exos@TMZ/RES delivery platform can provide a promising systemic chemotherapy strategy for enhancing GBM treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Yantai University, 30# Qingquan Road, Yantai, 264005, China.
- Pharmacy, Community Health Service Centre, Chujia Street, Laishan District, Yantai, 264003, China.
- Department of Neurosurgery, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China.
Förderung
- Natural Science Foundation of Shandong Province
- Yantai University
- Taishan Scholar Foundation of Shandong Province
- The Modern Agricultural Industry Technology System
Zitieren
APA
Wang, X., Zhang, T., Zhang, D., Cao, Y., Wang, X., Liu, X., Yang, W., Liu, Y., & Chen, D. (2025). Homologous tumor cell exosome-based drug delivery system co-delivering temozolomide and resveratrol for orthotopic glioblastoma therapy. Pharmaceutical Science Advances, 3, 100075. https://doi.org/10.1016/j.pscia.2025.100075
Vancouver
Wang X, Zhang T, Zhang D, Cao Y, Wang X, Liu X, et al. Homologous tumor cell exosome-based drug delivery system co-delivering temozolomide and resveratrol for orthotopic glioblastoma therapy. Pharmaceutical Science Advances. 2025;3:100075. doi:10.1016/j.pscia.2025.100075
BibTeX
@article{Wang2025,
author = {Wang, Xuemei and Zhang, Tao and Zhang, Dandan and Cao, Yuxin and Wang, Xinxin and Liu, Xiaowei and Yang, Weili and Liu, Yingchao and Chen, Daquan},
title = {Homologous tumor cell exosome-based drug delivery system co-delivering temozolomide and resveratrol for orthotopic glioblastoma therapy},
journal = {Pharmaceutical Science Advances},
year = {2025},
volume = {3},
pages = {100075},
doi = {10.1016/j.pscia.2025.100075}
}
EUVIMED